Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 22(10): 1438-1447, 2021 10.
Article
in En
| MEDLINE
| ID: mdl-34499874
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pleural Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Angiogenesis Inhibitors
/
Deoxycytidine
/
Antibodies, Monoclonal, Humanized
/
Mesothelioma, Malignant
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2021
Type:
Article
Affiliation country:
Italy